Dr. Steven Michael Couch, MD

Dr. Couch practices at Washington University in Saint Louis, Missouri.

Dr. Couch's NPI, 1578590634, was assigned on June 26, 2006. Dr. Couch graduated from UMKC School of Medicine in 2006. Dr. Couch holds Missouri license 2010014461.

Dr. Couch's primary practice is Washington University, at 10 Barnes West Dr, Saint Louis, MO 63141 in Saint Louis County. The practice phone is (314) 362-3937.

Dr. Couch's primary practice is Washington University in Saint Louis, Missouri. Dr. Couch is also affiliated with Barnes-Jewish Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Couch to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Couch practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Couch's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Couch is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Couch's licenses on file in 2 states: Missouri and Minnesota.

Dmand AI lists dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Couch treats.

CMS data shows 9,400 Medicare services from Dr. Couch across 13 procedure codes in 2024, for 393 Medicare patients. Medicare paid $137,712 for them. Every service was in an office.

CMS counts 393 Medicare patients who saw Dr. Couch in 2024. The largest group is 65 to 74, with 162 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Couch's median patient age at 73, with 67% women.

In 2024, Dr. Couch wrote 595 Medicare Part D claims for 318 patients. 90% of them were for generic drugs. CMS names the drug for 471 of them, across 5 drugs with 11 or more claims each, at $4,165 in total drug cost. In 2023, CMS named 475 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Couch for performance year 2024, reported as part of a group. Dr. Couch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 11 procedures of melanoma (skin cancer) excision by Dr. Couch, more than 64% of the clinicians it reports for that procedure.

Dmand AI links 53 papers to Dr. Couch, published from 2009 to 2025. 2015 was the busiest year, with 4. The most frequent topics are Blepharoplasty, Oculomotor Muscles and Eyelid Diseases. Dr. Couch has published most often in Ophthalmic Plast Reconstr Surg. Dr. Couch's most frequent co-authors are Robi Nicolas Maamari, MD, George John Harocopos, MD and Rao Venkatanarayana Chundury, MD.

Dmand AI links Dr. Couch to 3 clinical trials, 2 of them phase 4 studies. 1 is still active or recruiting. Conditions studied include Graves Ophthalmopathy, Exophthalmos and Muscle Spasticity. Amgen sponsors the most, 2.

CMS Open Payments shows 31 general payments to Dr. Couch from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Horizon Pharma plc paid the most, $1,000.

Dmand AI lists 2 awards for Dr. Couch, most recently CMS Stage 1 EHR in 2012.

Dr. Couch graduated from UMKC School of Medicine in 2006.

Dr. Couch is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.